Novartis receives Buy ratings from Kepler Capital and Deutsche Bank
Novartis AG received Buy ratings from Kepler Capital and Deutsche Bank, with both setting price targets of CHF135.00. The company reported quarterly revenue of CHF13.44 billion and net profit of CHF2.43 billion for the quarter ended December 31.
Novartis AG received Buy ratings from Kepler Capital and Deutsche Bank, with both setting a price target of CHF135.00. The company’s shares closed last Thursday at CHF123.20, while a stock listing showed 121.18 at close, up 1.15%.
Kepler Capital maintained a Buy rating on Novartis AG on April 2 and set a price target of CHF135.00. Deutsche Bank maintained a Buy rating on Novartis AG today and set a price target of CHF135.00.
In addition, Novartis AG also received a Buy from Bank of America Securities in a report issued on March 30, and a Buy from J.P. Morgan in a report issued today. However, Goldman Sachs maintained a Sell rating on March 31, and DZ BANK AG downgraded Novartis AG to a Hold on February 9.
Based on Novartis AG’s latest earnings release for the quarter ending December 31, the company reported quarterly revenue of CHF13.44 billion and net profit of CHF2.43 billion. In comparison, last year the company earned revenue of CHF13.56 billion and had net profit of CHF2.82 billion.
A stock listing showed previous close at 119.80, volume at 3.32M, 1 month return at -1.69%, 3 months return at 6.52%, 6 months return at 13.78%, and 1 year return at 36.71%.